If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Ginkgo Bioworks buys DNA supplier Gen9

Microbe maker back integrates by acquiring gene synthesis firm

by Ann M. Thayer
January 25, 2017 | A version of this story appeared in Volume 95, Issue 5

Photo of Ginkgo Bioworks’ synthetic biology foundry
Credit: Ginkgo Bioworks
Gen9’s technology will move into Ginkgo Bioworks’ synthetic biology foundry.

Synthetic biology firm Ginkgo Bioworks has acquired its DNA supplier Gen9 for an undisclosed amount. As a result, Gen9’s capabilities for synthesizing large amounts of DNA now directly feed into Ginkgo’s automated organism-engineering foundries.

Ginkgo uses the DNA to build customized multigene enzymatic pathways and microbial strains for clients such as Cargill and Archer Daniels Midland that are looking to produce chemicals and ingredients. In 2016, Gingko signed DNA supply deals with Gen9 and Twist Bioscience for a combined 600 million base pairs of DNA, an amount expected to be more than half the synthetic DNA market.

However, in late 2016, Boston news reports said that Gen9 had put orders on hold and was laying off sales staff. With the acquisition, Gen9’s operations and R&D teams will join Ginkgo. And Gen9’s BioFab manufacturing systems, which include proprietary technologies, software, and informatics tools, are being moved into Ginkgo’s facilities.

The opportunistic acquisition makes sense because of the companies’ existing relationship and proximity in the Boston-area, Lux Research analyst Victor Oh says. “It really just accelerated the inevitable by bringing that gene synthesis capability in-house to accelerate product development and project timelines.”

Oh says that timing was likely a factor. Gen9 appeared to be facing a decision of whether to raise money to expand so it could keep up with demand, or instead to join forces with its largest customer Ginkgo.

He anticipates that many of Gen9’s other customer relationships will probably continue.

Meanwhile, there’s still room in the market for other DNA suppliers. “Demand in the synthetic biology world is high and it keeps growing,” says Michael J. Kamdar, chief executive officer of Molecular Assemblies, a San Diego-based start-up developing enzyme-based DNA synthesis.

But further consolidation also wouldn’t come as a surprise among other companies that have relationships similar to the one between Ginkgo and Gen9, says Lux’s Oh. For example, microbe engineer Zymergen buys its DNA from nearby Twist. And like Ginkgo, Zymergen is ramping up its robotic production and signing on clients.



This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.